Stephen S. Yoder's most recent trade in Pieris Pharmaceuticals Inc was a trade of 634,021 Stock Option (Right to buy) done . Disclosure was reported to the exchange on Feb. 24, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pieris Pharmaceuticals Inc | Stephen S. Yoder | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 634,021 | 634,021 | - | - | Stock Option (Right to buy) | |
| Pieris Pharmaceuticals Inc | Stephen S. Yoder | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 625,874 | 625,874 | - | - | Stock Option (Right to buy) | |
| Pieris Pharmaceuticals Inc | Stephen S. Yoder | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 530,000 | 530,000 | - | - | Stock Options (Right to buy) |